| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802266901019 | 226690101 | LARIAM TAB 250 MG/TAB BTX8 | 10.16 | 10.66 | 14.69 |
For the treatment of mild to moderate acute malaria caused by Mefloquineuine-susceptible strains of <i>Plasmodium falciparum</i> (both chloroquine-susceptible and resistant strains) or by <i>Plasmodium vivax</i>. Also for the prophylaxis of <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> malaria infections, including prophylaxis of chloroquine-resistant strains of <i>Plasmodium falciparum</i>.
Mefloquine has been found to produce swelling of the <i>Plasmodium falciparum</i> food vacuoles. It may act by forming toxic complexes with free heme that damage membranes and interact with other plasmodial components.
Oral, rat: LD<sub>50</sub> = 880 mg/kg. Symptoms of overdose include nausea, vomiting, and weight loss.
Well absorbed from the gastrointestinal tract. The presence of food significantly enhances the rate and extent of absorption.
2 to 4 weeks
There is evidence that mefloquine is excreted mainly in the bile and feces. Urinary excretion of unchanged mefloquine and its main metabolite under steady-state condition accounted for about 9% and 4% of the dose, respectively.
* 20 L/kg [healthy adults]
* 30 mL/min